Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This also equates Bril as as being a arylamide-- "Brilacidin (PMX-30063) is a synthetic, nonpeptidic, small-molecule mimetic of HDPs [53,54,55,56,57,58] (Figure 1). Building on “first principles” in medicinal chemistry, rational design tools—leveraging sophisticated informatics to fine-tune physicochemical properties and structure–activity relationships [59,60,61]—enabled brilacidin (an arylamide foldamer [62,63]) to overcome the shortcomings and challenges that have complicated the clinical development of natural HDPs [64]. These include proteolytic degradation, toxicity, lack of efficacy, malabsorption, and high cost to produce. In contrast to natural HDPs, as well as other HDP analogs, brilacidin was designed de novo [65,66,67] to be much smaller, more stable, more potent, more selective, and more economical to manufacture. Brilacidin has already been successfully tested in clinical trials and shown to exhibit potent antibacterial activity in Phase 2 clinical trials for treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI), and anti-inflammatory activity, as supported in Phase 2 clinical trials for treatment of Ulcerative Proctitis/Ulcerative Proctosigmoiditis. As such, brilacidin has already demonstrated HDP-like therapeutic properties in the clinic".
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7916214/
Brilacidin, a non-peptide chemical mimic, is an arylamide foldamer designed to replicate the amphiphilic properties of antimicrobial peptides while solving the problems encountered by peptide-based antimicrobials. Per wikipedia.
It's not hot all over the temp around the mid-atlantic region is below average.
"A separate patent application has been submitted to the USPTO for use of Brilacidin in fungal diseases".
Work on a new fungal patent. Good going.
No doubt this could be a huge opportunity as epilepsy by itself is throughout the world. "BeaMed has successfully completed the manufacturing of its first-ever MRI compatible fiber optic probes, marking a major technical milestone in its development of an advanced laser technology with respect to shaping energy and matching it to patient specific anatomy, a novel concept that BeaMed is proving a reality resulting in a major milestone in the advancement of the StingRay System. The completion of these probes allows for comprehensive integration tests, involving the unique MRI compatible fiber optics, an MRI interface software suite, special algorithms to simplify damage estimation, and custom insertion tools, planned to commence in late June 2023".
An initial area of emphasis of the StingRay System will be for the treatment of epilepsy. Epilepsy affects millions of people worldwide, causing recurrent seizures that significantly diminish their quality of life. Traditional treatment methods, such as medication and surgery, possess limitations and may not be effective for all patients. Recognizing the critical need for innovation, BeaMed has developed an advanced laser system designed to revolutionize epilepsy treatment".
How Common Is Epilepsy?
By Mary Nolan-Pleckham, RN
Published on December 12, 2022
Medically reviewed by Smita Patel, MD
Each year, about 5 million people worldwide are diagnosed with epilepsy, a brain condition that causes repeated seizures.
World Health Organization (WHO).
It is estimated that about 1 in 100 people in the United States have active epilepsy. More than 75% of those are adults.
Hey Lemon. Agree! Merck may want a new patent since CAS is sold generic. CAS + B.
Caspofungin has a generic alternative so this could possibly incentivize Merck to do a combination trial with Brilacidin and if successful a new patent.
Possibly a competitor would be interested in the combination.
Bril disrupts the cell wall and this action coupled with fungistatic CAS make a fungicide. So both given together they have a fungicidal killer. Sounds huge.
"Taken together, BRI acts by impacting A. fumigatus calcineurin signaling and the cell wall integrity pathway converting the fungistatic action of CAS against A. fumigatus into a fungicidal drug".
Wow this thing shot straight up. Huge buys.
Per company pipeline-
Innovation Pharma owns rights to Brilacidin, a de novo-designed defensin-mimetic drug candidate exhibiting anti-inflammatory and antimicrobial properties. Brilacidin has been evaluated in multiple clinical trials (over 500 patients treated to date), received special FDA designations and can be administered via various modes of delivery.
I share your thoughts. Leo reported in vitro and in vivo studies seeing positive results (there's that "p" word). Also it was reported that further testing was planned by NIH/NIAID-affiliated and other academic researchers. I also believe we have a good shot at a deal. Good luck to us all. Btw you own a substantial lot. Go BeaMed!
WAKEFIELD, MA / March 15, 2023 Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, announced today that based on positive findings new testing of Brilacidin in additional in vitro and in vivo models against hard-to-treat fungal pathogens is planned by NIH/NIAID-affiliated and other academic researchers. Brilacidin is the Company’s defensin mimetic drug candidate exhibiting antimicrobial and immunomodulatory properties.
Participants improving significantly is good to see. Thanks for posting video georgejjl.
Your not being selfish, investors yearn for IPIX to recover and do well. God Bless you in your recovery.
Many thanks frenchbroad. Looking forward to upcoming reports.
We don't know just how many submissions they have but I bet each submission could take at least 30 days for an answer and then if the FDA has questions that could take longer. Hopefully a final answer some time in June. All just a guess but I remember reading sometime back that the FDA can take 45 days to reply.
Wow sounds like Dr Missling has already had a good look at the data. Maybe we will see the full data release during AAIC in July.
Some will be sold for sure but it all depends on the gravity of the news that gets us there.
It's not just the ceo, you have directors and many scientific advisers standing behind the reports.
Guarantee my doctor of medicine wouldn't have the time.
Your right. Thanks for that.
If kips sold it would generate a form-4.
Just wonderful to hear. All improvements returned when going back on A-273.
Yes "progress towards commercialization" is conclusive. That choice of words is a far cry from needing another trial.
ANAVEX®2-73 (BLARCAMESINE) PHASE 2B/3 STUDY MET PRIMARY AND KEY SECONDARY ENDPOINTS,
SHOWING STATISTICALLY SIGNIFICANT REDUCTION OF CLINICAL DECLINE IN GLOBAL CLINICAL STUDY OF PATIENTS WITH EARLY ALZHEIMER’S DISEASE
What data/numbers are you looking for.
To start Rett syndrome approved this year. It's an unmet need. I see it moving through US regulatory fairly quickly. AZ could see approval in Australia yet this year.
Other than that. Nice tick up.
I see it's now $8.43.
This should explain his post, Dr. Randi J. Hagerman is very bullish on results seen in Anavex A-273 - https://investorshub.advfn.com/boards/read_msg.aspx?message_id=171816711
Ask price by size
0.0198 x by 60000 shares
Volume
8,379
Agree, I believe there would be great appeal for a safe blood pressure medication that's non diuretic.
Thanks for posting cantwate. Having in vivo studies is progress to a higher level.
I believe Dr Missiling to be on the up and up and that's why I bought shares. Trading works both ways if company insiders found data not good wouldn't they be dumping as well.
My understanding is leadership schedule their buys by calendar date.
Message I got said said not excepting calls not that it was disconnected. 978-921-4125. Leo doesn't exude confidence in his business acumen that's for sure. I continue to hold but just don't have much interest in this thing anymore. Things can change with the right news beyond just testing.
4:17 Ready for commercialization. Just to hear Dr Missling say it WOW!
Battle of the mm's happening.
"New in vivo data in an A. fumigatus murine fungal keratitis model showed brilacidin reduced fungal burden and disease severity, while also improving corneal thickness compared to control. brilacidin-treated corneas harbored almost no viable fungus, suggesting the compound suppressed fungal proliferation within the cornea. Worldwide, on an annual basis, fungal keratitis affects up to 1.5 million people, of whom 75 percent may lose an eye and/or their sight".
You brought the proof frenchbroad.
More animal model testing planned
"Planned next steps in brilacidin antifungal research include extending in vitro and in vivo testing into additional clinical isolates and animal models, and publishing scientific findings. In collaboration with the NIH/NIAID’s mycology division, brilacidin also is to be screened in multiple fungal species to further characterize its broad-spectrum antifungal activity. Future updates are planned".
Not true. Multiple CNS trials have demonstrated and shown proof of A-273 efficacy. Now we wait for regulatory guidance.